Notice: This company has been marked as potentially delisted and may not be actively trading. LogicBio Therapeutics (LOGC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsInsider TradesOptions ChainShort InterestSustainabilityTrends LOGC vs. SELB, EDIT, QURE, VYGR, SGMO, MYTE, JMIA, SFIX, HNST, and BYONShould you be buying LogicBio Therapeutics stock or one of its competitors? The main competitors of LogicBio Therapeutics include Selecta Biosciences (SELB), Editas Medicine (EDIT), uniQure (QURE), Voyager Therapeutics (VYGR), Sangamo Therapeutics (SGMO), MYT Netherlands Parent B.V. (MYTE), Jumia Technologies (JMIA), Stitch Fix (SFIX), Honest (HNST), and Beyond (BYON). LogicBio Therapeutics vs. Selecta Biosciences Editas Medicine uniQure Voyager Therapeutics Sangamo Therapeutics MYT Netherlands Parent B.V. Jumia Technologies Stitch Fix Honest Beyond Selecta Biosciences (NASDAQ:SELB) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Which has more risk and volatility, SELB or LOGC? Selecta Biosciences has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, LogicBio Therapeutics has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Does the MarketBeat Community prefer SELB or LOGC? Selecta Biosciences received 240 more outperform votes than LogicBio Therapeutics when rated by MarketBeat users. However, 64.08% of users gave LogicBio Therapeutics an outperform vote while only 55.63% of users gave Selecta Biosciences an outperform vote. CompanyUnderperformOutperformSelecta BiosciencesOutperform Votes33155.63% Underperform Votes26444.37% LogicBio TherapeuticsOutperform Votes9164.08% Underperform Votes5135.92% Does the media prefer SELB or LOGC? In the previous week, Selecta Biosciences' average media sentiment score of 0.00 equaled LogicBio Therapeutics'average media sentiment score. Company Overall Sentiment Selecta Biosciences Neutral LogicBio Therapeutics Neutral Do analysts prefer SELB or LOGC? Given Selecta Biosciences' higher possible upside, research analysts clearly believe Selecta Biosciences is more favorable than LogicBio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Selecta Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ALogicBio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Do insiders and institutionals have more ownership in SELB or LOGC? 42.0% of Selecta Biosciences shares are held by institutional investors. Comparatively, 46.1% of LogicBio Therapeutics shares are held by institutional investors. 31.2% of Selecta Biosciences shares are held by company insiders. Comparatively, 0.4% of LogicBio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is SELB or LOGC more profitable? Selecta Biosciences has a net margin of -72.04% compared to LogicBio Therapeutics' net margin of -141.03%. Selecta Biosciences' return on equity of -44.13% beat LogicBio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Selecta Biosciences-72.04% -44.13% -22.00% LogicBio Therapeutics -141.03%-109.05%-62.15% Which has higher valuation and earnings, SELB or LOGC? Selecta Biosciences has higher earnings, but lower revenue than LogicBio Therapeutics. LogicBio Therapeutics is trading at a lower price-to-earnings ratio than Selecta Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSelecta Biosciences$110.78M0.00$35.38M-$0.22N/ALogicBio Therapeutics$287M0.58-$317M-$9.10-0.70 SummarySelecta Biosciences beats LogicBio Therapeutics on 8 of the 13 factors compared between the two stocks. Ad Porter & CompanyI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get LogicBio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LOGC vs. The Competition Export to ExcelMetricLogicBio TherapeuticsCatalog & mail IndustryRetail SectorNASDAQ ExchangeMarket Cap$167.63M$1.32B$23.63B$8.49BDividend YieldN/A1.76%3.41%4.17%P/E Ratio-0.705.49107.7813.61Price / Sales0.580.526.2790.86Price / CashN/A18.2419.6633.51Price / Book0.712.357.625.10Net Income-$317M-$7.68M$690.12M$224.54M LogicBio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LOGCLogicBio Therapeutics0.4469 of 5 stars$6.37-0.2%N/AN/A$167.63M$287M-0.7062SELBSelecta BiosciencesN/AN/AN/AN/A$136.76M$110.78M-4.0164Gap DownHigh Trading VolumeEDITEditas Medicine4.6577 of 5 stars$2.88-1.0%$9.91+244.1%-65.3%$237.54M$78.12M-1.22230Analyst DowngradeNews CoverageHigh Trading VolumeQUREuniQure1.8886 of 5 stars$5.56-5.1%$19.50+250.7%-9.1%$285.37M$15.84M-0.94500VYGRVoyager Therapeutics4.1738 of 5 stars$6.65-5.0%$17.43+162.1%-0.9%$381.73M$250.01M23.75100Analyst UpgradeSGMOSangamo Therapeutics2.0293 of 5 stars$1.74-7.4%$2.67+53.3%+278.3%$391.45M$176.23M-1.26480Upcoming EarningsMYTEMYT Netherlands Parent B.V.0.5949 of 5 stars$6.19-0.6%$4.88-21.2%+90.5%$531.21M$909.70M-20.631,817JMIAJumia Technologies2.3135 of 5 stars$4.62+1.1%$7.30+58.0%+71.1%$462.20M$186.40M0.002,915Upcoming EarningsSFIXStitch Fix2.1257 of 5 stars$3.37+3.7%$3.27-3.0%-6.6%$412.22M$1.34B-3.124,570HNSTHonest3.0504 of 5 stars$3.84+2.1%$5.04+31.1%+209.7%$376.31M$344.36M-29.54190Upcoming EarningsBYONBeyond3.6446 of 5 stars$6.34-0.2%$16.50+160.3%N/A$292.39M$1.56B-0.861,050 Related Companies and Tools Related Companies Selecta Biosciences Alternatives Editas Medicine Alternatives uniQure Alternatives Voyager Therapeutics Alternatives Sangamo Therapeutics Alternatives MYT Netherlands Parent B.V. Alternatives Jumia Technologies Alternatives Stitch Fix Alternatives Honest Alternatives Beyond Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LOGC) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LOGC Stock Alerts